Participant characteristics and assessments used in this study
| Participant characteristics and assessments (assessments will be collected in a random order to avoid order effect) | Phase 1 | Phase 2 | |
| T1 | T2 | T3 | |
| Participant identifier (ID) | X | X | X |
| Age | X | X | |
| Gender | X | X | |
| MS phenotype* | X | X | |
| Disease duration | X | X | |
| EDSS† | X | X | |
| DMT‡ | X | X | X |
| (Pre-final) German version of Unidimensional Self-Efficacy Scale for Multiple Sclerosis | X | X | X |
| Qualitative cognitive interview | X | ||
| Resilience Scale, short version | X | X | |
| General Self-Efficacy Scale | X | X | |
| Multiple Sclerosis International Quality of Life questionnaire | X | X | |
| Hospital Anxiety and Depression Scale | X | X | |
| Neurological Fatigue Index | X | X | |
*Relapsing-remitting; primary progressive; secondary progressive multiple sclerosis.95
†EDSS groups: 0–4.0; 4.5–6.5; 7.0–7.5; 8.0–9.0.30
‡(a) No DMTs; (b) low effective DMTs: interferon-b 1a and 1b, pegylated interferon-b 1a, glatiramer acetate, dimethyl fumarate, teriflunomide, azathioprin, intravenous immunoglobulins; (c) high effective DMTs: alemtuzumab, cladribine, fingolimod, natalizumab, ocrelizumab, cyclophosphamide, mitoxantrone, rituximab.96 ,97
DMT, disease modifying treatment; EDSS, Expanded Disability Status Scale.